Hyperkalemia

In late May, shares of Relypsa Inc (NASDAQ: RLYP) soared when the FDA rejected AstraZeneca plc (ADR) (NYSE: AZN)’s hyperkalemia drug ZS-9. The market is betting that the rejection will be good news for Relypsa’s Veltassa, which also treats hyperkalemia. Slingshot Insights recently held...

Shares of AstraZeneca plc (ADR) (NYSE: AZN) were trading lower by more than 1.5 percent early Friday after the company confirmed it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration relating to its New Drug Application (NDA) for sodium zirconium cyclosilicate,...

On May 16, Relypsa Inc (NASDAQ: RLYP) released the launch metrics for Veltassa for the month of April. H.C. Wainwright’s Ed Arce reiterated a Buy rating on the company, with a price target of $32. ‘New Starts’ Down Arce mentioned that “New Starts” were marginally down...

On its 1Q call, Relypsa Inc (NASDAQ: RLYP) highlighted the challenges it had been facing in gaining patient access for its hyperkalemia treatment, Veltassa. BTIG’s Timothy Chiang maintains a Buy rating on the company, while lowering the price target from $45 to $35. Estimates Lowered Chiang...

Relypsa Inc (NASDAQ: RLYP) shares plunged more than 18 percent after Mizuho Securities downgraded the stock to Underperform from Neutral, saying the near-term buyout of the company is "unlikely" following its recent $150 million debt offering. "We view this event (offering) as a sign that near-term...

Liana Moussatos of Wedbush overviewed the emerging pharmaceuticals space and offered a scenario analysis of various potential catalysts. Moussatos has the highest degree of confidence on two upcoming catalysts for Relypsa Inc (NASDAQ: RLYP), one of which could see its stock move up or down by as...